A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques.
The minimum requirement for candidate human immunodeficiency virus (HIV) vaccines to enter clinical evaluation in humans should be their demonstrable immunogenicity in non-human primates: induction of antibodies neutralizing primary HIV isolates or elicitation of broad T cell-mediated immune respons...
Main Authors: | Wee, E, Patel, S, Mcmichael, A, Hanke, T |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2002
|
Similar Items
-
Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice.
by: Hanke, T, et al.
Published: (2005) -
Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.
by: Im, E, et al.
Published: (2006) -
Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models
by: Lynette Siv Chea, et al.
Published: (2017-10-01) -
Development of a DNA-MVA/HIVA vaccine for Kenya.
by: Hanke, T, et al.
Published: (2002) -
Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine.
by: Nixon, D, et al.
Published: (2000)